Lilly's Alimta combination cancer therapy fails trial
Sept 6 (Reuters) - Eli Lilly and Co said a late-stage trial testing its lung cancer drug Alimta failed to meet the main study goal of improving overall survival of patients.
Patients on the trial, named Pointbreak, were given either a combination of Alimta and Roche Holding AG's cancer drug Avastin along with chemotherapy, or just Avastin along with chemotherapy drugs.
- White House reverses, says Obama met uncle and lived with him during law school
- South Africans, some fearful, wake to life without Mandela |
- U.S. television, Twitter, alive with new version of 'Sound of Music'
- RPT-UPDATE 1-Ford leans on global Mustang to burnish overseas image
- Ford leans on global Mustang to burnish overseas image